Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Octopus Biosafety's revenue for the
six
months ended in Dec. 2024 was €0.05 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €0.05 Mil.
Octopus Biosafety's Revenue per Share for the
six
months ended in Dec. 2024 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00.
Warning Sign:
Octopus Biosafety revenue per share has been in decline over the past 3 years.
During the past 10 years, Octopus Biosafety's highest 3-Year average Revenue per Share Growth Rate was -35.20% per year. The lowest was -38.30% per year. And the median was -36.75% per year.
Octopus Biosafety (STU:OCR) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Octopus Biosafety Revenue Related Terms
Octopus Biosafety Revenue Historical Data
* Premium members only.
The historical data trend for Octopus Biosafety's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Computer Hardware subindustry, Octopus Biosafety's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Octopus Biosafety Revenue vs Hardware Industry
For the Hardware industry and Technology sector, Octopus Biosafety's Revenue distribution charts can be found below:
* The bar in red indicates where Octopus Biosafety's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Octopus Biosafety (STU:OCR) has a Revenue of €0.05 Mil as of Dec. 2024. Revenue is the total amount a company generates as sales through its operations. View historical data on Octopus Biosafety and its competitors.
Is Octopus Biosafety's Revenue too high?
Octopus Biosafety's current Revenue is €0.05 Mil. Overall, Octopus Biosafety has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does Octopus Biosafety's Revenue compare to DELL and ANET?
Octopus Biosafety's Revenue of €0.05 Mil can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Hardware company?
A good Revenue depends on the Hardware industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Octopus Biosafety and its competitors. Octopus Biosafety's current Revenue is €0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Octopus Biosafety stock overvalued right now?
Octopus Biosafety (STU:OCR) has a current Revenue of €0.05 Mil. The stock's GF Value™ is €0.05, compared to a current price of €0.10 — trading 100% above its estimated fair value. The current Revenue is €0.05 Mil. Octopus Biosafety's overall GF Score™ is 1/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Octopus Biosafety (STU:OCR), the current Revenue is €0.05 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Octopus Biosafety (STU:OCR) Overvalued in 2026?
Based on GuruFocus' analysis, Octopus Biosafety stock appears to be overvalued.
The current stock price of €0.10 is trading 100% above its estimated GF Value™ of €0.05.
Key valuation signals for STU:OCR:
Revenue: €0.05 Mil
GF Value™: €0.05 vs. price of €0.10 (100% above fair value)
No single metric tells the full story. See the STU:OCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Octopus Biosafety is engaged in the design, manufacture and marketing of mobile, autonomous, intelligent and modular robots for use in Agro-food sector, Healthcare sector, Defense sector, Civil Protection sector, and Surveillance and Transport sector.
1GF Score
Get the complete analysis for STU:OCR
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OCR has been successfully added to your 
